BriaCell Therapeutics
Its mission has been to develop novel immunotherapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $2.1m | Grant | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
BriaCell Therapeutics Corp. is a biotechnology company focused on developing novel immunotherapies to combat cancer, with an initial emphasis on advanced metastatic breast cancer. The company operates in the biopharmaceutical sector, targeting patients with breast cancer that has spread to other tissues. BriaCell's core product, Bria-OTS, is a personalized off-the-shelf cellular immunotherapy currently undergoing Phase 1/2 clinical trials. The business model revolves around the development and commercialization of these immunotherapies, aiming to offer safer and more effective alternatives to traditional chemotherapy. Revenue is generated through the successful development, approval, and commercialization of their therapies, as well as potential partnerships and licensing agreements. BriaCell's market includes healthcare providers, cancer treatment centers, and patients seeking advanced cancer therapies. The company is listed on Nasdaq under the ticker symbols BCTX and BCTXW, and on the TSX under BCT.
Keywords: immunotherapy, breast cancer, metastatic, biotechnology, clinical trials, personalized medicine, off-the-shelf, biopharmaceutical, cancer treatment, Nasdaq.